Scarica l'app Stockscreener
8.31
0.73%
0.07
Precedente Chiudi:
$8.24
Aprire:
$8.36
Volume 24 ore:
879.23K
Relative Volume:
1.30
Capitalizzazione di mercato:
$448.48M
Reddito:
-
Utile/perdita netta:
$-86.60M
Rapporto P/E:
-2.9339
EPS:
-2.8324
Flusso di cassa netto:
$-67.37M
1 W Prestazione:
+28.28%
1M Prestazione:
+60.23%
6M Prestazione:
+319.19%
1 anno Prestazione:
+1.34%
Intervallo 1D:
$8.21
$8.5999
Intervallo di 1 settimana:
$7.75
$8.88
Portata 52W:
$1.45
$11.72
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Confronta LXEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
8.305 | 444.97M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Using data filters to optimize entry into Lexeo Therapeutics Inc.Treasury Yields & AI Forecasted Stock Moves - newser.com
Can Lexeo Therapeutics Inc. stock double in next 5 yearsMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Will Lexeo Therapeutics Inc. stock outperform Nasdaq indexSell Signal & Precise Swing Trade Entry Alerts - newser.com
Using flow based indicators on Lexeo Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockInsider Selling & AI Enhanced Trading Alerts - newser.com
Leerink Partnrs Issues Positive Forecast for LXEO Earnings - Defense World
Lexeo Therapeutics, Inc.: A Deep Dive (NASDAQ:LXEO) - Seeking Alpha
How to monitor Lexeo Therapeutics Inc. with trend dashboardsMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Smart tools for monitoring Lexeo Therapeutics Inc.’s price action2025 Pullback Review & Daily Stock Trend Reports - newser.com
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease - streetwisereports.com
Analyzing recovery setups for Lexeo Therapeutics Inc. investorsJobs Report & Verified Chart Pattern Signals - newser.com
Biotech Firm Uncovers Breakthrough Gene Therapy in New York - streetwisereports.com
How to integrate Lexeo Therapeutics Inc. into portfolio analysis toolsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Is a relief rally coming for Lexeo Therapeutics Inc. holdersWeekly Profit Summary & Free Weekly Watchlist of Top Performers - newser.com
Lexeo Therapeutics Announces Progress in FDA Discussions and Positive Interim Data for LX2006 - TradingView
Is Lexeo Therapeutics Inc. a candidate for recovery playBond Market & Free Community Consensus Stock Picks - newser.com
Why Lexeo Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Reactions & Community Supported Trade Ideas - newser.com
Therapeutics Company Advances Gene Therapy Breakthrough - streetwisereports.com
Lexeo Therapeutics reports on LX2006 approval pathway - MSN
Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating - MarketScreener
HC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Leerink Partners Issues Positive Forecast for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In - Stocktwits
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha
Lexeo, FDA position Friedreich ataxia therapy for accelerated path - BioWorld MedTech
Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target - TipRanks
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits
Lexeo says FDA open to speedier approval of rare disease gene therapy - BioPharma Dive
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment - MarketScreener
Lexeo up after regulatory update on ataxia drug (LXEO:NASDAQ) - Seeking Alpha
Lexeo’s gene therapy for Friedreich ataxia shows promising results By Investing.com - Investing.com Canada
Lexeo Therapeutics Advances FDA Discussions for LX2006 - TipRanks
Lexeo Therapeutics announces progress in FDA discussions for LX006 in Friedreich ataxia cardiomyopathy - MarketScreener
Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway for LX2006 in Friedreich Ataxia with Promising Interim Data - Quiver Quantitative
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Progress In FDA Discussions For LX006 In Friedreich Ataxia Cardiomyopathy - TradingView
23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan
Can a trend reversal in Lexeo Therapeutics Inc. lead to recoveryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Lexeo Therapeutics Inc. stock a top momentum playRate Hike & Daily Growth Stock Investment Tips - newser.com
Can Lexeo Therapeutics Inc. recover in the next quarterDip Buying & Verified Swing Trading Watchlist - newser.com
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Robertson Jenny | Chief Legal Officer |
Aug 18 '25 |
Sale |
4.67 |
542 |
2,530 |
62,556 |
| Adler Eric | Chief Medical Officer |
Aug 18 '25 |
Sale |
4.67 |
608 |
2,838 |
67,073 |
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '25 |
Sale |
4.67 |
2,735 |
12,767 |
220,058 |
| See Tai Sandi | Chief Development Officer |
Aug 18 '25 |
Sale |
4.67 |
382 |
1,783 |
58,860 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):